drugset / Trial / NCT00454389

A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration

NCT00454389

Phase 3 Unknown 494 enrolled NeoVista
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of the CABERNET Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration (AMD). The Epi-Rad90™ Ophthalmic System treats neovascularization of retinal tissue by means of a focal, directional delivery of radiation to the target tissues in the retina. Using standard vitreoretinal surgical techniques, the sealed radiation source is placed temporarily over the retinal lesion by means of a handheld medical device.

Timeline

Start
2007-04
Primary completion
2011-09
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranibizumab Monoclonal antibody

Indications